4-IODO-6-PHENYLPYRIMIDINE
| 中文名称 | 4-IODO-6-PHENYLPYRIMIDINE |
|---|---|
| 中文同义词 | 4-碘-6-苯基嘧啶;化合物4-IPP;4-IPP,巨噬细胞迁移抑制因子(MIF)抑制剂;化合物4-IPP,10 MM DMSO 溶液;【进口原装】4-IPP/41270-96-6;【进口原装】4-IPP/41270-96-6 |
| 英文名称 | 4-IODO-6-PHENYLPYRIMIDINE |
| 英文同义词 | 4-IODO-6-PHENYLPYRIMIDINE;4-IPP;MIF Antagonist III, 4-IPP;MIF Antagonist III, 4-IPP - CAS 41270-96-6 - Calbiochem;Pyrimidine, 4-iodo-6-phenyl-;4-IPP (4-Iodo-6-phenylpyrimidine);Inhibitor,osteoclastogenesis,4IPP,MIF,4-IPP,inhibit,4 IPP,RANKL,osteoblast;4-IPP, 10 mM in DMSO |
| CAS号 | 41270-96-6 |
| 分子式 | C10H7IN2 |
| 分子量 | 282.08 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | Mol File |
| 结构式 |  |
4-IODO-6-PHENYLPYRIMIDINE 性质
| 沸点 | 380.2±30.0 °C(Predicted) |
|---|---|
| 密度 | 1.728±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 在DMSO中的溶解度为10mg/mL（透明溶液，加热） |
| 形态 | 粉末 |
| 酸度系数(pKa) | -0.54±0.17(Predicted) |
| 颜色 | 白色至米色 |
| InChI | 1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H |
| InChIKey | ZTCJXHNJVLUUMR-UHFFFAOYSA-N |
| SMILES | Ic1cc(ncn1)-c2ccccc2 |
| Target | Value |
|
MIF
() |
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption .
Cell Cytotoxicity Assay
| Cell Line: | BMMs |
| Concentration: | 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM |
| Incubation Time: | 24 hours, 72 hours |
| Result: | Inhibited osteoclastogenesis in a dose-dependent manner. |
Western Blot Analysis
| Cell Line: | BMMs |
| Concentration: | 5 μM,10 μM, 20 μM |
| Incubation Time: | 1 day, 3 days, 5 days |
| Result: | Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation.
| Animal Model: | 8-weeks-old C57BL/6J male mice |
| Dosage: | 1 mg/kg, 5 mg/kg |
| Administration: | Intraperitoneal injection; every 2 days; for 8 weeks |
| Result: | Alleviated OVX-induced osteoporosis. |
安全信息
| 危险品标志 | Xn |
|---|---|
| 危险类别码 | 22-37/38-41 |
| 安全说明 | 26-39 |
| WGK Germany | 3 |
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-110063 | 4-IPP | 41270-96-6 | 1 mg | 400元 |
| 2025/12/22 | HY-110063 | 4-IODO-6-PHENYLPYRIMIDINE 4-IPP | 41270-96-6 | 5mg | 1150元 |